Your browser doesn't support javascript.
loading
Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy.
Li, Zhenxian; Zhu, Haimei; Liu, Hao; Liu, Dayue; Liu, Jianhe; Jiang, Jiazheng; Zhang, Yi; Qin, Zhang; Xu, Yijia; Peng, Yuan; Liu, Bin; Long, Yun.
Afiliación
  • Li Z; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Zhu H; Department of Pain, The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, China.
  • Liu H; Department of Rehabilitation, The Second Xiangya Hospital, Central South University, Changsha, 410011, China.
  • Liu D; Department of Physiology and Pathophysiology, NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, 750004, China.
  • Liu J; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Jiang J; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Zhang Y; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Qin Z; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Xu Y; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Peng Y; Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Changsha, 410007, China.
  • Liu B; College of Biology, Hunan University, Changsha, 410082, China. binliu2001@hotmail.com.
  • Long Y; Department of Physiology and Pathophysiology, NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, 750004, China. binliu2001@hotmail.com.
J Nanobiotechnology ; 21(1): 158, 2023 May 19.
Article en En | MEDLINE | ID: mdl-37208681
PCSK9, which is closely related to atherosclerosis, is significantly expressed in vascular smooth muscle cells (VSMCs). Moreover, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) mediated phenotypic transformation, abnormal proliferation, and migration of VSMCs play key roles in accelerating atherosclerosis. In this study, by utilizing the significant advantages of nano-materials, a biomimetic nanoliposome loading with Evolocumab (Evol), a PCSK9 inhibitor, was designed to alleviate atherosclerosis. In vitro results showed that (Lipo + M)@E NPs up-regulated the levels of α-SMA and Vimentin, while inhibiting the expression of OPN, which finally result in the inhibition of the phenotypic transition, excessive proliferation, and migration of VSMCs. In addition, the long circulation, excellent targeting, and accumulation performance of (Lipo + M)@E NPs significantly decreased the expression of PCSK9 in serum and VSMCs within the plaque of ApoE-/- mice.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aterosclerosis / Proproteína Convertasa 9 Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aterosclerosis / Proproteína Convertasa 9 Límite: Animals Idioma: En Revista: J Nanobiotechnology Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido